## IN THE UNITED STATES PATENT AND TRADEMARK-OFFICE

In re l	Patent	Application of OVE			#8
KOK	URA	et al ( 007 0.1 2002 )	Atty. Ref.:	925-165	#8 10-3-02
Serial	No.	09/696,220 RADEMARIA	Group:	1775	1 800
Filed:		October 26, 2000	Examiner:	unknown	
For:		TTERNED SUBSTRATE AND LIQUID CREPLAY PROVIDED THEREWITH  * * * * * * * * * * * * * * * * * * *	XYSTAL * * * *	ı	
		ommissioner for Patents a, DC 20231			
Sir:		INFORMATION DISCLOSURE	STATEMEN	<u>T</u>	RECEIVED OCT - 2 2032 C 1700 MAIL R
$\boxtimes$	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office]	ce Action]	N/C	RECEIVED  OCT - 2 2032  1700 MAIL ROOM
	2.	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance]		N/C	<b>.</b>
	3.	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance]		\$180.00	
	4.	Pursuant to 37 CFR 1.97(d) [before Issue Fee payment]		\$180.00	
	The	following are submitted in the above-identified	d application in	n compliance	e with 37
C.F.R	. §§ 1.	97 and 1.98:			
$\boxtimes$	5.	A list of documents on Form PTO-1449 togo identified document and a translation or a content English language document is enclosed here	non-		
		a) The partial translations were provided foreign representative. The undersigned pertinency of the partially translated por The partial translations are merely provided.	ed has no knov ortions vis-á-vi	vledge regards	ding the ent as a whole.

This paper is submitted in accordance with:

$\boxtimes$	6.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]					
	7.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and					
		a) The required Statement made in item 9 below; or					
		b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 10 below.					
	8.	37 CFR §1.97(d): [before issue fee payment]; and					
		a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and					
		b) The required Statement is stated in item 9 below.					
	9.	Statement under 37 CFR 1.97(e)					
		a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or					
		b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
	10. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.						
		Respectfully submitted,					
		NIXON & VANDERHYE P.C.					
Octo	ber 1,	By: Salance Burnam, Jr.					
HWB		Reg. No. 29,366					
1100 North Glebe Road, 8th Floor							
•	Arlington, VA 22201-4714 Telephone: (703) 816-4000						
Facsimile: (703) 816-4100							